Dihydroergotamine Mesylate is a small molecule commercialized by Satsuma Pharmaceuticals, with a leading Phase III program in Migraine. According to Globaldata, it is involved in 5 clinical trials, of which 4 were completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Dihydroergotamine Mesylate’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Dihydroergotamine Mesylate is expected to reach an annual total of $83 mn by 2033 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Dihydroergotamine Mesylate Overview
Dihydroergotamine mesylate (STS-101, TO-2070) is under development for the treatment of acute migraine. The drug candidate is an ergot alkaloid that acts on 5-HT1D antimigraine receptors. It is administered through nasal dry powder drug delivery system. TO-2070 is based on a nasal powder drug delivery technology that combines a muco-adhesive drug carrier with a proprietary nasal powder drug delivery device.
Satsuma Pharmaceuticals Overview
Satsuma Pharmaceuticals (Satsuma) is biopharmaceutical company. It develops novel therapies for neurological diseases. It is investigating its lead pipeline candidate STS101 is a proprietary investigational drug-device combination product which enables intranasal administration of the anti-migraine drug, dihydroergotamine mesylate (DHE). The company is funded by RA Capital Management, TPG Biotech, Shin Nippon Biomedical Laboratories, Osage University Partners, CAM Capital, and Eventide Asset Management LLC. Satsuma is headquartered in South San Francisco, California, the US.
The operating loss of the company was US$51.2 million in FY2021, compared to an operating loss of US$48.3 million in FY2020. The net loss of the company was US$51.2 million in FY2021, compared to a net loss of US$47.6 million in FY2020.
For a complete picture of Dihydroergotamine Mesylate’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.